secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0000950170-24-029207
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX FY2023 revenue $101.2M, operating expenses down 30%; BMS discontinues 986288, CX-904 data H2 2024
--------------------------------------------------------------------------------

- FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).
- Cash $174.5M at Dec 31, 2023 vs $193.7M a year earlier; includes $30M from July 2023 BVF financing.
- BMS notified CytomX it will not continue BMS-986288 beyond current Phase 2; research collaboration with multiple TCE programs continues.
- CX-904 EGFRxCD3 Phase 1a data expected H2 2024; CX-2051 and CX-801 Phase 1 starts H1 2024 after IND clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/0000950170-24-029207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017024029207/ctmx-20240311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-029207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer